These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 32815856)

  • 1. Radiographic Response of Vessel Involvement and Resectability After Neoadjuvant Chemoradiation in Patients With Locally Advanced Pancreatic Cancer.
    Naumann P; Ottensmeier F; Farnia B; Ben-Josef E; Liermann J; Maier-Hein KH; Hackert T; Debus J
    Am J Clin Oncol; 2020 Nov; 43(11):776-783. PubMed ID: 32815856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Objective Assessment of Surgical Restaging after Concurrent Chemoradiation for Locally Advanced Pancreatic Cancer.
    Paik WH; Lee SH; Kim YT; Park JM; Song BJ; Ryu JK
    J Korean Med Sci; 2015 Jul; 30(7):917-23. PubMed ID: 26130955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tolerability and Long-term Outcomes of Dose-Painted Neoadjuvant Chemoradiation to Regions of Vessel Involvement in Borderline or Locally Advanced Pancreatic Cancer.
    Wo JY; Niemierko A; Ryan DP; Blaszkowsky LS; Clark JW; Kwak EL; Lillemoe KD; Drapek LN; Zhu AX; Allen JN; Faris JE; Murphy JE; Nipp R; Fernandez-Del Castillo C; Ferrone CR; Hong TS
    Am J Clin Oncol; 2018 Jul; 41(7):656-661. PubMed ID: 28134673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma.
    Hu Q; Wang D; Chen Y; Li X; Cao P; Cao D
    Radiat Oncol; 2019 Jul; 14(1):120. PubMed ID: 31291998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic impact of CA 19-9 on outcome after neoadjuvant chemoradiation in patients with locally advanced pancreatic cancer.
    Combs SE; Habermehl D; Kessel KA; Bergmann F; Werner J; Naumann P; Jäger D; Büchler MW; Debus J
    Ann Surg Oncol; 2014 Aug; 21(8):2801-7. PubMed ID: 24916745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Characteristics of Patients Experiencing Pathologic Complete Response Following Neoadjuvant Therapy for Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma.
    Hashemi-Sadraei N; Gbolahan OB; Salfity H; O'Neil B; House MG; Shahda S
    Am J Clin Oncol; 2018 Oct; 41(10):982-985. PubMed ID: 28968257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolonged Neoadjuvant Therapy for Locally Advanced Pancreatic Cancer.
    Eguchi H; Yamada D; Iwagami Y; Gotoh K; Kawamoto K; Wada H; Asaoka T; Noda T; Takeda Y; Tanemura M; Sakai D; Satoh T; Kudo T; Isohashi F; Mori M; Doki Y
    Dig Surg; 2018; 35(1):70-76. PubMed ID: 28482348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Arterial involvement and resectability scoring system to predict R0 resection in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation therapy.
    Noda Y; Pisuchpen N; Mercaldo ND; Sekigami Y; Michelakos T; Parakh A; Wo JY; Qadan M; Ferrone C; Lillemoe KD; Ryan DP; Clark JW; Fernandez-Del Castillo C; Hong TS; Kambadakone AR
    Eur Radiol; 2022 Apr; 32(4):2470-2480. PubMed ID: 34665317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome of Patients with Borderline Resectable Pancreatic Cancer in the Contemporary Era of Neoadjuvant Chemotherapy.
    Javed AA; Wright MJ; Siddique A; Blair AB; Ding D; Burkhart RA; Makary M; Cameron JL; Narang A; Herman J; Zheng L; Laheru D; Weiss MJ; Wolfgang C; He J
    J Gastrointest Surg; 2019 Jan; 23(1):112-121. PubMed ID: 30242644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant chemoradiotherapy for locally advanced pancreas cancer rarely leads to radiological evidence of tumour regression.
    Dudeja V; Greeno EW; Walker SP; Jensen EH
    HPB (Oxford); 2013 Sep; 15(9):661-7. PubMed ID: 23458352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intraoperative Radiation Therapy (IORT) for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (BR/LA PDAC) in the Era of Modern Neoadjuvant Treatment: Short-Term and Long-Term Outcomes.
    Harrison JM; Wo JY; Ferrone CR; Horick NK; Keane FK; Qadan M; Lillemoe KD; Hong TS; Clark JW; Blaszkowsky LS; Allen JN; Castillo CF
    Ann Surg Oncol; 2020 May; 27(5):1400-1406. PubMed ID: 31758284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiographic patterns of first disease recurrence after neoadjuvant therapy and surgery for patients with resectable and borderline resectable pancreatic cancer.
    Barnes CA; Aldakkak M; Christians KK; Clarke CN; Dua K; George B; Ritch PS; Kamgar M; Hall WA; Kulkarni N; Erickson BA; Evans DB; Tsai S
    Surgery; 2020 Sep; 168(3):440-447. PubMed ID: 32641278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal timing and treatment strategy for pancreatic cancer.
    Gamboa AC; Rupji M; Switchenko JM; Lee RM; Turgeon MK; Meyer BI; Russell MC; Cardona K; Kooby DA; Maithel SK; Shah MM
    J Surg Oncol; 2020 Sep; 122(3):457-468. PubMed ID: 32470166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes after resection of locally advanced or borderline resectable pancreatic cancer after neoadjuvant therapy.
    Barugola G; Partelli S; Crippa S; Capelli P; D'Onofrio M; Pederzoli P; Falconi M
    Am J Surg; 2012 Feb; 203(2):132-9. PubMed ID: 21824596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of borderline and locally advanced pancreatic cancer: where do we stand?
    He J; Page AJ; Weiss M; Wolfgang CL; Herman JM; Pawlik TM
    World J Gastroenterol; 2014 Mar; 20(9):2255-66. PubMed ID: 24605025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Locally advanced pancreatic adenocarcinoma: reassessment of response with CT after neoadjuvant chemotherapy and radiation therapy.
    Cassinotto C; Mouries A; Lafourcade JP; Terrebonne E; Belleannée G; Blanc JF; Lapuyade B; Vendrely V; Laurent C; Chiche L; Wagner T; Sa-Cunha A; Gaye D; Trillaud H; Laurent F; Montaudon M
    Radiology; 2014 Oct; 273(1):108-16. PubMed ID: 24960211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant chemoradiation with IMRT in resectable and borderline resectable pancreatic cancer.
    Kharofa J; Tsai S; Kelly T; Wood C; George B; Ritch P; Wiebe L; Christians K; Evans DB; Erickson B
    Radiother Oncol; 2014 Oct; 113(1):41-6. PubMed ID: 25443499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: international survey and case-vignette study.
    Heinrich S; Besselink M; Moehler M; van Laethem JL; Ducreux M; Grimminger P; Mittler J; Lang H; Lutz MP; Lesurtel M;
    BMC Cancer; 2019 Jul; 19(1):675. PubMed ID: 31288786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Role of Radiation Therapy for Pancreatic Cancer in the Adjuvant and Neoadjuvant Settings.
    Badiyan SN; Molitoris JK; Chuong MD; Regine WF; Kaiser A
    Surg Oncol Clin N Am; 2017 Jul; 26(3):431-453. PubMed ID: 28576181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary resection versus neoadjuvant chemoradiation followed by resection for locally resectable or potentially resectable pancreatic carcinoma without distant metastasis. A multi-centre prospectively randomised phase II-study of the Interdisciplinary Working Group Gastrointestinal Tumours (AIO, ARO, and CAO).
    Brunner TB; Grabenbauer GG; Meyer T; Golcher H; Sauer R; Hohenberger W
    BMC Cancer; 2007 Mar; 7():41. PubMed ID: 17338829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.